AI assistant
Probi — AGM Information 2012
Oct 24, 2012
3099_rns_2012-10-24_bac6c36d-ccc2-4e55-b0a6-386746a1f879.pdf
AGM Information
Open in viewerOpens in your device viewer
PRESS RELEASE
Information submitted for publication on 24 October 2012 at 8:30 (CET).
Nomination Committee at Probi AB
Probi's Nomination Committee prior to the 2013 Annual General Meeting comprises the following individuals:
Heinz-Jürgen Bertram, Symrise Erik Sjöström, Skandia Bengt Jeppsson, Professor in the surgery unit, Lund University
Erik Sjöström and Bengt Jeppsson were appointed at Probi's Annual General Meeting on 26 April 2012. Heinz-Jürgen Bertram, CEO Symrise, replaces Ragnhild Wiborg, Consepio, pursuant to the policy procedure for changes in the ownership structure, as established at the Annual General Meeting on 26 April 2012.
The Annual General Meeting of Probi AB will be held in Lund on Wednesday 24 April 2013, at 15.00 (CET).
Shareholders who would like to contact the Nomination Committee may do so by letter addressed to "Nomination Committee, Probi AB, att: Sofie Forsman, Ideon Gamma 1, SE-223 70 Lund, Sweden" or by e-mailing [email protected]
Shareholders who would like an item addressed at the Annual General Meeting must submit a written proposal to the Chairman of the Board not later than Friday 8 March 2013. Such proposals must be sent by letter addressed to "Annual General Meeting, Probi AB, att: Sofie Forsman, Ideon Gamma 1, SE-223 70 Lund, Sweden", or by e-mail to [email protected].
This is the type of information that Probi AB is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
FOR MORE INFORMATION, PLEASE CONTACT:
Per Lundin, Chairman of the Board, Probi, mobile +46 705 74 11 71, e-mail: [email protected] Michael Oredsson, CEO, Probi, tel +46 46 286 89 23 or mobile +46 707 18 89 30 e-mail: [email protected]
ABOUT PROBI
Probi is a leading player in probiotic research and the development of efficient and well-documented probiotics. Its research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi's customers are leading companies in the functional foods and consumer healthcare business areas. Total income for 2011 totalled MSEK 95.0. Probi's share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders. For moreinformation, please visit www.probi.se.